US20040044045A1 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents - Google Patents
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents Download PDFInfo
- Publication number
- US20040044045A1 US20040044045A1 US10/621,195 US62119503A US2004044045A1 US 20040044045 A1 US20040044045 A1 US 20040044045A1 US 62119503 A US62119503 A US 62119503A US 2004044045 A1 US2004044045 A1 US 2004044045A1
- Authority
- US
- United States
- Prior art keywords
- thienyl
- dihydroxy
- cyclopentyl
- lower alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title description 4
- 239000003814 drug Substances 0.000 title description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 title description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 title description 2
- HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 title description 2
- 229940124597 therapeutic agent Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 109
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 27
- 239000001257 hydrogen Substances 0.000 claims abstract description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 14
- 229910052736 halogen Chemical group 0.000 claims abstract description 9
- 125000005843 halogen group Chemical group 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 52
- -1 alkyl radical Chemical class 0.000 claims description 33
- 208000010412 Glaucoma Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 206010030043 Ocular hypertension Diseases 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000002997 ophthalmic solution Substances 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 229940054534 ophthalmic solution Drugs 0.000 claims description 3
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims 2
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 13
- 150000003180 prostaglandins Chemical class 0.000 abstract description 13
- 230000001077 hypotensive effect Effects 0.000 abstract description 8
- 208000001953 Hypotension Diseases 0.000 abstract description 4
- 208000021822 hypotensive Diseases 0.000 abstract description 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 121
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 50
- 239000002253 acid Substances 0.000 description 43
- 238000002360 preparation method Methods 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- 239000000243 solution Substances 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- 125000001544 thienyl group Chemical class 0.000 description 21
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 0 *CCC(C)ccC1C(C)CC(C)C1CccCCCC(C)[Y] Chemical compound *CCC(C)ccC1C(C)CC(C)C1CccCCCC(C)[Y] 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 13
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 125000000950 dibromo group Chemical group Br* 0.000 description 7
- 230000004410 intraocular pressure Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- ZXGVFUKWWWNTTQ-VSGBNLITSA-N (3r,5r)-7-[4-[[3-(2-amino-2-oxoethyl)phenyl]sulfamoyl]-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)CCN1C(C(C)C)=C(S(=O)(=O)NC=2C=C(CC(N)=O)C=CC=2)C(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 ZXGVFUKWWWNTTQ-VSGBNLITSA-N 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- VKSQACUFUOXWSJ-UHFFFAOYSA-N 1-dimethoxyphosphoryl-4-thiophen-3-ylbutan-2-one Chemical compound COP(=O)(OC)CC(=O)CCC=1C=CSC=1 VKSQACUFUOXWSJ-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- UWKQJZCTQGMHKD-UHFFFAOYSA-N 2,6-di-tert-butylpyridine Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=N1 UWKQJZCTQGMHKD-UHFFFAOYSA-N 0.000 description 2
- NVVPMZUGELHVMH-UHFFFAOYSA-N 3-ethyl-4-[4-[4-(1-methylpyrazol-4-yl)imidazol-1-yl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-1-yl]benzamide Chemical compound CCC1=CC(C(N)=O)=CC=C1N1C2=NC=CC(N3C=C(N=C3)C3=CN(C)N=C3)=C2C(C(C)C)=N1 NVVPMZUGELHVMH-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
- VWVKUNOPTJGDOB-BDHVOXNPSA-N Anhydrous tofogliflozin Chemical compound C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 VWVKUNOPTJGDOB-BDHVOXNPSA-N 0.000 description 2
- ZJQUKGUSGZEXSV-CEFQEYTGSA-N CC1=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)NS(=O)(=O)C(F)(F)F)C=CS1 Chemical compound CC1=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)NS(=O)(=O)C(F)(F)F)C=CS1 ZJQUKGUSGZEXSV-CEFQEYTGSA-N 0.000 description 2
- NUVBHCDVLLPRRH-IOVLCUHKSA-N CC1=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)NS(C)(=O)=O)C=CS1 Chemical compound CC1=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)NS(C)(=O)=O)C=CS1 NUVBHCDVLLPRRH-IOVLCUHKSA-N 0.000 description 2
- TXFTYOWNAGTAQM-UOENFZOCSA-N CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(C)SC=C1 Chemical compound CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(C)SC=C1 TXFTYOWNAGTAQM-UOENFZOCSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- XTTLFJKOSULUND-DUALGHOESA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CSC=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CSC=C1 XTTLFJKOSULUND-DUALGHOESA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 2
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- PRLVHZDMICRVJF-UHFFFAOYSA-N cyclopentane;heptanoic acid Chemical compound C1CCCC1.CCCCCCC(O)=O PRLVHZDMICRVJF-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- DAAXYQZSKBPJOX-FQEVSTJZSA-N (2S)-2-amino-3-[4-[5-[3-(4-hydroxyphenyl)-4-methoxyphenyl]-1,2,4-oxadiazol-3-yl]phenyl]propanoic acid Chemical compound COC1=C(C=C(C=C1)C2=NC(=NO2)C3=CC=C(C=C3)C[C@@H](C(=O)O)N)C4=CC=C(C=C4)O DAAXYQZSKBPJOX-FQEVSTJZSA-N 0.000 description 1
- SLTBMTIRYMGWLX-XMMPIXPASA-N (2r)-2-[(4-chloroanilino)carbamoylamino]-3-(1h-indol-3-yl)-n-(2-phenylethyl)propanamide Chemical compound C1=CC(Cl)=CC=C1NNC(=O)N[C@@H](C(=O)NCCC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 SLTBMTIRYMGWLX-XMMPIXPASA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 1
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 1
- LPNRUMVKXCLEBE-JXVRESAISA-L (3r)-4-[[(e)-2-[5-ethyl-4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-oxidophosphoryl]-3-hydroxybutanoate Chemical compound CCC1=C(C=2C=CC=CC=2)N=C(C(C)C)C(\C=C\P([O-])(=O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 LPNRUMVKXCLEBE-JXVRESAISA-L 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- YCGQPIRMLGEWMW-UHFFFAOYSA-N 1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN(C)C)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 YCGQPIRMLGEWMW-UHFFFAOYSA-N 0.000 description 1
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 1
- OXTVBHDILDPYAS-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 OXTVBHDILDPYAS-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- KDTPPFOGDBHGKI-UHFFFAOYSA-N 1-dimethoxyphosphoryl-4-(1,3-thiazol-2-yl)butan-2-one Chemical compound COP(=O)(OC)CC(=O)CCC1=NC=CS1 KDTPPFOGDBHGKI-UHFFFAOYSA-N 0.000 description 1
- IVBKIMUBUJLMJA-UHFFFAOYSA-N 1-dimethoxyphosphoryl-4-(furan-2-yl)butan-2-one Chemical compound COP(=O)(OC)CC(=O)CCC1=CC=CO1 IVBKIMUBUJLMJA-UHFFFAOYSA-N 0.000 description 1
- WNKKNLAUKXSGPL-UHFFFAOYSA-N 1-dimethoxyphosphoryl-4-(furan-3-yl)butan-2-one Chemical compound COP(=O)(OC)CC(=O)CCC=1C=COC=1 WNKKNLAUKXSGPL-UHFFFAOYSA-N 0.000 description 1
- GMZQKLKBNXNCFE-UHFFFAOYSA-N 1-dimethoxyphosphoryl-4-thiophen-2-ylbutan-2-one Chemical compound COP(=O)(OC)CC(=O)CCC1=CC=CS1 GMZQKLKBNXNCFE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CJLZUKCACMUYFP-GOSISDBHSA-N 2-[(5R)-4-[2-[3-(3-methylbutanoyloxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound CC(C)CC(=O)OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 CJLZUKCACMUYFP-GOSISDBHSA-N 0.000 description 1
- AKBHYCHPWZPGAH-UHFFFAOYSA-N 2-[3-[(3-chloro-4-methylphenyl)methoxy]azetidine-1-carbonyl]-7-oxa-5-azaspiro[3.4]octan-6-one Chemical compound CC1=C(Cl)C=C(COC2CN(C2)C(=O)C2CC3(C2)COC(=O)N3)C=C1 AKBHYCHPWZPGAH-UHFFFAOYSA-N 0.000 description 1
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical compound COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- YSKRGAISRCYGRK-UHFFFAOYSA-N 4-(1-benzofuran-2-yl)-1-dimethoxyphosphorylbutan-2-one Chemical compound C1=CC=C2OC(CCC(=O)CP(=O)(OC)OC)=CC2=C1 YSKRGAISRCYGRK-UHFFFAOYSA-N 0.000 description 1
- HWFBUSZTGOPWFF-UHFFFAOYSA-N 4-(1-benzothiophen-2-yl)-1-dimethoxyphosphorylbutan-2-one Chemical compound C1=CC=C2SC(CCC(=O)CP(=O)(OC)OC)=CC2=C1 HWFBUSZTGOPWFF-UHFFFAOYSA-N 0.000 description 1
- LIDUGWDLSDKCLM-CSKARUKUSA-N 4-[[3-[[[(e)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]methyl-dimethylsilyl]benzonitrile Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(OC[Si](C)(C)C=2C=CC(=CC=2)C#N)=C1 LIDUGWDLSDKCLM-CSKARUKUSA-N 0.000 description 1
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- AIJULSRZWUXGPQ-UHFFFAOYSA-N CC(=O)C=O Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 1
- UXOZQFNBWDOCRI-XAPDPLRESA-N CC(=O)OCN(C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1)S(C)(=O)=O Chemical compound CC(=O)OCN(C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1)S(C)(=O)=O UXOZQFNBWDOCRI-XAPDPLRESA-N 0.000 description 1
- FSBVTVVMXMZLGP-PKLXCVOVSA-N CC(C)(C)C(=O)OCN(C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1)S(C)(=O)=O Chemical compound CC(C)(C)C(=O)OCN(C(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1)S(C)(=O)=O FSBVTVVMXMZLGP-PKLXCVOVSA-N 0.000 description 1
- PCIVNNMWVVVVGL-JQWTWWEKSA-N CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(C#N)S1 Chemical compound CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(C#N)S1 PCIVNNMWVVVVGL-JQWTWWEKSA-N 0.000 description 1
- ROFOYHUJIJFJDZ-CEFQEYTGSA-N CC1=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)C=CS1 Chemical compound CC1=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)C=CS1 ROFOYHUJIJFJDZ-CEFQEYTGSA-N 0.000 description 1
- OVNRHAANPLLRPI-CEFQEYTGSA-N CC1=CC(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)=CS1 Chemical compound CC1=CC(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)=CS1 OVNRHAANPLLRPI-CEFQEYTGSA-N 0.000 description 1
- NLXZYKDSUWLVHR-LCFFHJSBSA-N CC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 Chemical compound CC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 NLXZYKDSUWLVHR-LCFFHJSBSA-N 0.000 description 1
- KDIFTKOIHCNBOI-NDBVFQRCSA-N CCC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 Chemical compound CCC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 KDIFTKOIHCNBOI-NDBVFQRCSA-N 0.000 description 1
- JYIBUUMUQFNVOS-YDMSRQNGSA-N CCCC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 Chemical compound CCCC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 JYIBUUMUQFNVOS-YDMSRQNGSA-N 0.000 description 1
- ZTKRCHBIUFPSIT-IQMJRDIISA-N CCCCC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 Chemical compound CCCCC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 ZTKRCHBIUFPSIT-IQMJRDIISA-N 0.000 description 1
- XQBLDWHZDVEWHH-WQCKVPOQSA-N CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1 Chemical compound CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1 XQBLDWHZDVEWHH-WQCKVPOQSA-N 0.000 description 1
- PDKGWXAVJHPKJT-WQCKVPOQSA-N CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Cl)S1 Chemical compound CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Cl)S1 PDKGWXAVJHPKJT-WQCKVPOQSA-N 0.000 description 1
- ZXMIWGQNTSAUQP-WQCKVPOQSA-N CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(I)S1 Chemical compound CCS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(I)S1 ZXMIWGQNTSAUQP-WQCKVPOQSA-N 0.000 description 1
- CNMFHDIDIMZHKY-UHFFFAOYSA-N COC(=O)C(C)(C)C Chemical compound COC(=O)C(C)(C)C CNMFHDIDIMZHKY-UHFFFAOYSA-N 0.000 description 1
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 1
- MRPQCQBCHSLGKG-QHGAWSKTSA-N COC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 Chemical compound COC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 MRPQCQBCHSLGKG-QHGAWSKTSA-N 0.000 description 1
- YEFFLXOHZKXIEV-LUGGRYCLSA-N CO[C@@H](CCc1c[s]cc1)/C=C/[C@H](C[C@H](C1)O)[C@@H]1O Chemical compound CO[C@@H](CCc1c[s]cc1)/C=C/[C@H](C[C@H](C1)O)[C@@H]1O YEFFLXOHZKXIEV-LUGGRYCLSA-N 0.000 description 1
- NOMYNYIJVQFWEW-CEFQEYTGSA-N CO[C@H](/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O)CCC1=CSC=C1 Chemical compound CO[C@H](/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O)CCC1=CSC=C1 NOMYNYIJVQFWEW-CEFQEYTGSA-N 0.000 description 1
- ZSORINRJVCNUAB-QHGAWSKTSA-N CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1 Chemical compound CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1 ZSORINRJVCNUAB-QHGAWSKTSA-N 0.000 description 1
- JXYFKPZQOIQIIY-QHGAWSKTSA-N CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Cl)S1 Chemical compound CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Cl)S1 JXYFKPZQOIQIIY-QHGAWSKTSA-N 0.000 description 1
- PAMVPEKFFITMCL-QHGAWSKTSA-N CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(I)S1 Chemical compound CS(=O)(=O)NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(I)S1 PAMVPEKFFITMCL-QHGAWSKTSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010067684 Iris bombe Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- GFWJLKTWXLMRJO-IKKFLOODSA-N N#CC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 Chemical compound N#CC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(=O)O)S1 GFWJLKTWXLMRJO-IKKFLOODSA-N 0.000 description 1
- WEYHPWPXGFHBBC-IKKFLOODSA-N N#CC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(N)=O)S1 Chemical compound N#CC1=CC=C(CC[C@H](O)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\CCCC(N)=O)S1 WEYHPWPXGFHBBC-IKKFLOODSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ALNHYDLSRWZMHE-MJNWZANWSA-N NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)SC(Cl)=C1 Chemical compound NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)SC(Cl)=C1 ALNHYDLSRWZMHE-MJNWZANWSA-N 0.000 description 1
- SILKRYPYYZBSIN-MNRSVHRVSA-N NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(F)C=CS1 Chemical compound NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(F)C=CS1 SILKRYPYYZBSIN-MNRSVHRVSA-N 0.000 description 1
- PTGLLMVWPQDRSQ-DUALGHOESA-N NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CSC=C1 Chemical compound NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CSC=C1 PTGLLMVWPQDRSQ-DUALGHOESA-N 0.000 description 1
- PTGLLMVWPQDRSQ-YTRVLTIVSA-N NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=CSC=C1 Chemical compound NC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=CSC=C1 PTGLLMVWPQDRSQ-YTRVLTIVSA-N 0.000 description 1
- 206010068960 Narrow anterior chamber angle Diseases 0.000 description 1
- ZQUZIHBELAMMKN-OPWDAOPCSA-N O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1)NS(=O)(=O)C(F)(F)F Chemical compound O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1)NS(=O)(=O)C(F)(F)F ZQUZIHBELAMMKN-OPWDAOPCSA-N 0.000 description 1
- BAZJUICTARZBGO-OPWDAOPCSA-N O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Cl)S1)NS(=O)(=O)C(F)(F)F Chemical compound O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Cl)S1)NS(=O)(=O)C(F)(F)F BAZJUICTARZBGO-OPWDAOPCSA-N 0.000 description 1
- CYRRUVKZHCDTQD-OPWDAOPCSA-N O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(I)S1)NS(=O)(=O)C(F)(F)F Chemical compound O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(I)S1)NS(=O)(=O)C(F)(F)F CYRRUVKZHCDTQD-OPWDAOPCSA-N 0.000 description 1
- HGMHVKRQGRZGBT-MNRSVHRVSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)C=CS1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)C=CS1 HGMHVKRQGRZGBT-MNRSVHRVSA-N 0.000 description 1
- ALUCEWLCJFGQOC-MJNWZANWSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)SC(Cl)=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)SC(Cl)=C1 ALUCEWLCJFGQOC-MJNWZANWSA-N 0.000 description 1
- VWTGQAXUJVEIRO-CIFLLGDISA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)SC=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(Cl)SC=C1 VWTGQAXUJVEIRO-CIFLLGDISA-N 0.000 description 1
- QBEUPRURZVOXLX-MNRSVHRVSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(F)C=CS1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=C(F)C=CS1 QBEUPRURZVOXLX-MNRSVHRVSA-N 0.000 description 1
- NOQNNPBVERQJGR-HUIKGJIMSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC(Br)=CS1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC(Br)=CS1 NOQNNPBVERQJGR-HUIKGJIMSA-N 0.000 description 1
- DZVPCZZOQJLWLZ-SLPSQVGLSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC2=C(C=CC=C2)O1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC2=C(C=CC=C2)O1 DZVPCZZOQJLWLZ-SLPSQVGLSA-N 0.000 description 1
- MBIMWFIIUAFUBN-SLPSQVGLSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC2=C(C=CC=C2)S1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC2=C(C=CC=C2)S1 MBIMWFIIUAFUBN-SLPSQVGLSA-N 0.000 description 1
- DJXQXIUBTBCAOW-OPWDAOPCSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=C(Br)S1 DJXQXIUBTBCAOW-OPWDAOPCSA-N 0.000 description 1
- YAOJHFGKRDGWBD-VLKKHCNFSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CO1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CO1 YAOJHFGKRDGWBD-VLKKHCNFSA-N 0.000 description 1
- ITAOLCLVRZZZQP-VLKKHCNFSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CS1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CS1 ITAOLCLVRZZZQP-VLKKHCNFSA-N 0.000 description 1
- GKBCZRZJCRGILF-DUALGHOESA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=COC=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=COC=C1 GKBCZRZJCRGILF-DUALGHOESA-N 0.000 description 1
- QLAZFGOOUWOWCY-WRZGLRELSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=NC=CS1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=NC=CS1 QLAZFGOOUWOWCY-WRZGLRELSA-N 0.000 description 1
- ITAOLCLVRZZZQP-OZOLXXCYSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=CC=CS1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=CC=CS1 ITAOLCLVRZZZQP-OZOLXXCYSA-N 0.000 description 1
- XTTLFJKOSULUND-YTRVLTIVSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=CSC=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=CSC=C1 XTTLFJKOSULUND-YTRVLTIVSA-N 0.000 description 1
- QLAZFGOOUWOWCY-KRUCDZGJSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=NC=CS1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@H](O)CCC1=NC=CS1 QLAZFGOOUWOWCY-KRUCDZGJSA-N 0.000 description 1
- QQMMXSLYNYKKFS-PJYQEOKXSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CCC(O)CCC1=COC=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CCC(O)CCC1=COC=C1 QQMMXSLYNYKKFS-PJYQEOKXSA-N 0.000 description 1
- ASJIXUZDNARSFY-SCZZCJEKSA-N O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CSC=C1 Chemical compound O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CSC=C1 ASJIXUZDNARSFY-SCZZCJEKSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000001326 acute closed-angle glaucoma Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- CDVMXMZPDJHSCC-UHFFFAOYSA-N chembl1684662 Chemical compound C=1C=C2C=C(C=3C4=NC=CC=C4NN=3)NC2=CC=1CC(=O)C1=CC=CC=C1 CDVMXMZPDJHSCC-UHFFFAOYSA-N 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126212 compound 17a Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 229940125880 compound 4j Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- KUCDOJMOTMEEOF-UHFFFAOYSA-N gtpl6345 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(SC=2C3=C4NCCOC4=CN=2)=C3N=C1 KUCDOJMOTMEEOF-UHFFFAOYSA-N 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- FEQPHYCEZKWPNE-UHFFFAOYSA-K trichlororhodium;triphenylphosphane Chemical compound Cl[Rh](Cl)Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 FEQPHYCEZKWPNE-UHFFFAOYSA-K 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
- C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Definitions
- the present invention relates to cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives which may be substituted in the 1-position with hydroxyl, alkyloxy, amino and amido groups, e.g. 1-OH cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives.
- These compounds are potent ocular hypotensive and are particularly suited for the management of glaucoma.
- Ocular hypotensive agents are useful in the treatment of a number of various ocular hypertensive conditions, such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts.
- Glaucoma is a disease of the eye characterized by increased intraocular pressure. On the basis of its etiology, glaucoma has been classified as primary or secondary. For example, primary glaucoma in adults (congenital glaucoma) may be either open-angle or acute or chronic angle-closure. Secondary glaucoma results from pre-existing ocular diseases such as uveitis, intraocular tumor or an enlarged cataract.
- the underlying causes of primary glaucoma are not yet known.
- the increased intraocular tension is due to the obstruction of aqueous humor outflow.
- chronic open-angle glaucoma the anterior chamber and its anatomic structures appear normal, but drainage of the aqueous humor is impeded.
- acute or chronic angle-closure angle-closure glaucoma the anterior chamber is shallow, the filtration angle is narrowed, and the iris may obstruct the trabecular meshwork at the entrance of the canal of Schlemm. Dilation of the pupil may push the root of the iris forward against the angle, and may produce pupilary block and thus precipitate an acute attack. Eyes with narrow anterior chamber angles are predisposed to acute angle-closure glaucoma attacks of various degrees of severity.
- Secondary glaucoma is caused by any interference with the flow of aqueous humor from the posterior chamber into the anterior chamber and subsequently, into the canal of Schlemm.
- Inflammatory disease of the anterior segment may prevent aqueous escape by causing complete posterior synechia in iris bombe, and may plug the drainage channel with exudates.
- Other common causes are intraocular tumors, enlarged cataracts, central retinal vein occlusion, trauma to the eye, operative procedures and intraocular hemorrhage.
- glaucoma occurs in about 2% of all persons over the age of 40 and may be asymptotic for years before progressing to rapid loss of vision.
- topical b-adrenoreceptor antagonists have traditionally been the drugs of choice for treating glaucoma.
- Eicosanoids and their derivatives have been reported to possess ocular hypotensive activity, and have been recommended for use in glaucoma management.
- Eicosanoids and derivatives include numerous biologically important compounds such as prostaglandins and their derivatives.
- Prostaglandins can be described as derivatives of prostanoic acid which have the following structural formula:
- prostaglandins are known, depending on the structure and substituents carried on the alicyclic ring of the prostanoic acid skeleton. Further classification is based on the number of unsaturated bonds in the side chain indicated by numerical subscripts after the generic type of prostaglandin [e.g. prostaglandin E 1 (PGE 1 ), prostaglandin E 2 (PGE 2 )], and on the configuration of the substituents on the alicyclic ring indicated by ⁇ or ⁇ [[e.g. prostaglandin F 2 ⁇ (PGF 2 ⁇ )].
- PGE 1 prostaglandin E 1
- PGE 2 prostaglandin E 2
- Prostaglandins were earlier regarded as potent ocular hypertensives, however, evidence accumulated in the last decade shows that some prostaglandins are highly effective ocular hypotensive agents, and are ideally suited for the long-term medical management of glaucoma (see, for example, Bito, L. Z. Biological Protection with Prostaglandins, Cohen, M. M., ed., Boca Raton, Fla., CRC Press Inc., 1985, pp. 231-252; and Bito, L. Z., Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S. M. and Neufeld, A. H.
- Such prostaglandins include PGF 2 ⁇ , PGF 1 ⁇ , PGE 2 , and certain lipid-soluble esters, such as C 1 to C 2 alkyl esters, e.g. 1-isopropyl ester, of such compounds.
- prostaglandins appear to be devoid of significant intraocular side effects
- ocular surface (conjunctival) hyperemia and foreign-body sensation have been consistently associated with the topical ocular use of such compounds, in particular PGF 2 ⁇ and its prodrugs, e.g., its 1-isopropyl ester, in humans.
- the clinical potentials of prostaglandins in the management of conditions associated with increased ocular pressure, e.g. glaucoma are greatly limited by these side effects.
- 11,15-9,15 and 9,11-diesters of prostaglandins for example 11,15-dipivaloyl PGF 2 ⁇ are known to have ocular hypotensive activity. See the co-pending patent applications U.S. Ser. No. Nos. 385,645 (filed Jul. 07, 1989, now U.S. Pat. Nos. 4,994,274), 584,370 (filed Sep. 18, 1990, now U.S. Pat. Nos. 5,028,624) and 585,284 (filed Sep. 18, 1990, now U.S. Pat. No. 5,034,413). The disclosures of all of these patent applications are hereby expressly incorporated by reference.
- the present invention concerns a method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound of formula I
- R 5 represents hydrogen or CH 2 OR 6 and R 6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical, e.g. a fluoro substituted lower alkyl radical; Y is ⁇ O or represents 2 hydrogen radicals, and 1, 9, 11 or 15 esters thereof.
- the present invention relates to an ophthalmic solution comprising a therapeutically effective amount of a compound of formula (I), wherein the symbols have the above meanings, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application.
- the substituents on the heteroaryl radical may be selected from the group consisting of lower alkyl, e.g. C 1 to C 6 alkyl; halogen, e.g. fluoro, chloro and bromo; trifluoromethyl (CF 3 ); COR 1 , e.g. COCH 3 ; COCF 3 ; SO 2 NR 1 , e.g. SO 2 NH 2 ; NO 2 ; CN; etc.
- the present invention relates to a pharmaceutical product, comprising
- a container adapted to dispense its contents in a metered form
- FIG. 1 is a schematic of the chemical synthesis of certain 1-carboxylic acid compounds of the invention specifically disclosed as Example 4(a)-(v) below.
- FIG. 2 is a schematic of the chemical synthesis of certain ⁇ -substituted thienyl 1-carboxylic acid compound of the invention specifically disclosed as Examples 6 and 6(a), below.
- FIG. 3 is a schematic of the chemical synthesis of certain 1-amido compounds of the invention specifically disclosed as Examples 8(p)-(q), below.
- FIG. 4 is a schematic of the chemical synthesis of certain -substituted thienyl 1-carboxylic acid compounds.
- FIG. 5 is a schematic of the chemical synthesis of ⁇ -substituted furanyl-1-carboxylic acid compounds specifically disclosed as Example 15.
- the present invention relates to the use of cyclopentane heptan(ene)oic acid, 2-heteroaryl alkenyl derivatives as therapeutic agents, e.g. as ocular hypotensives.
- the compounds or derivatives used in accordance with the present invention are encompassed by the above structural formula I:
- Z is selected from the group consisting of O and S
- A is selected from the group consisting of N, —CH, and C
- R 2 is selected from the group consisting of hydrogen, halogen, and lower alkyl having from 1 to 6 carbon atoms
- R 3 and R 4 are selected from the group consisting of hydrogen, halogen, lower alkyl having from 1 to 6 carbon atoms, or, together with
- R 3 and R 4 forms a condensed aryl ring.
- X is —N(R 1 ) 2
- Y is ⁇ O.
- At least one of R 2 , R 3 or R 4 are independently selected from the group consisting of chloro, bromo and lower alkyl.
- at least one of R 2 , R 3 or R 4 is chloro or bromo, and more preferably at least one of R 2 , R 3 or R 4 is bromo or at least two of R 2 , R 3 or R 4 are chloro.
- at least one of R 2 , R 3 or R 4 is ethyl, propyl, or butyl.
- R 5 is hydrogen or CH 2 OH, wherein the OH group is esterified with acetic acid or pivalic acid, i.e. R 5 is
- R6 is methyl, ethyl or trifluoromethyl.
- Another preferred group includes compounds having the formula IV:
- R 5 is hydrogen or methyl
- the above compounds of the present invention may be prepared by methods that are known in the art or according to the working examples below.
- the compounds, below, are especially preferred representative of the compounds of the present invention.
- a pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered.
- salts formed with inorganic ions such as sodium, potassium, calcium, magnesium and zinc.
- compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable acid addition salt thereof, as an active ingredient, with conventional ophthalmically acceptable pharmaceutical excipients, and by preparation of unit dosage forms suitable for topical ocular use.
- the therapeutically efficient amount typically is between about 0.0001 and about 5% (w/v), preferably about 0.001 to about 1.0% (w/v) in liquid formulations.
- solutions are prepared using a physiological saline solution as a major vehicle.
- the pH of such ophthalmic solutions should preferably be maintained between 6.5 and 7.2 with an appropriate buffer system.
- the formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.
- Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate.
- a preferred surfactant is, for example, Tween 80.
- various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.
- Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.
- buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
- an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
- excipient components which may be included in the ophthalmic preparations are chelating agents.
- the preferred chelating agent is edentate disodium, although other chelating agents may also be used in place or in conjunction with it.
- ingredients are usually used in the following amounts: Ingredient Amount (% w/v) active ingredient about 0.001-5 preservative 0-0.10 vehicle 0-40 tonicity adjustor 1-10 buffer 0.01-10 pH adjustor q.s. pH 4.5-7.5 antioxidant as needed surfactant as needed purified water as needed to make 100%
- the actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.
- the ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate the application to the eye.
- Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution.
- Step 3 Preparation of 7-[3 ⁇ ,5 ⁇ -Dihydroxy-2-(3 ⁇ -hydroxy-5-(3-(2-methyl)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- Lactone 11 (170 mg, 0.315 mmol) was dissolved in CH 2 Cl 2 (1.0 mL) and cooled to ⁇ 70° C. Dibal-H(0.47 mL of a 1.0 M solution in CH 2 Cl 2 , 0.47 mmol) was added. After 2 h the reaction was quenched with MeOH, allowed to warm to room temperature, and extracted with CH 2 Cl 2 . The organic portion was dried (Na 2 SO 4 ), filtered and concentrated in vacuo to give the lactol as a clear, viscous oil.
- Step 1 Preparation of ketone 14.
- Step 2 Preparation of 7-[3 ⁇ ,5 ⁇ -Dihydroxy-2-(3-hydroxy-5-(3-furanyl)pentyl)cyclopentyl]-5Z-heptenoic acid 15.
- TP-vasoconstrictor activity was measured as contraction of rings of the isolated rat thoracic aorta. Effects on platelets from healthy human donors were measured by incubating platelet-rich plasma with the compounds described herein. Inhibition of aggregation was determined by the ability of the compounds described herein to inhibit platelet aggregation in platelet-rich plasma induced by 20 ⁇ M ADP.
- EP 3 receptors In addition to stimulating the FP receptor associated with the cat iris, several examples also stimulated the EP 3 receptor. Compounds with agonist activity at EP 3 receptors may also be used for treating gastric or duodenal ulcer by virtue of their cytoprotective and anti-secretory properties. They may also be used as adjunctive therapy in combination with aspirin-like drugs and steroids to limit gastrointestinal side effects. EP 3 agonists stimulate uterine smooth muscle and may be used to terminate pregnancy in human females. EP 3 agonists are also useful in the cervical ripening process and could be used for inducing labor.
- FP VASC FP vascular endothelium in the rabbit jugular vein preparation. Since such agents would be vasodilators they have potential in hypertension and any disease where tissue blood perfusion is compromised. Such indications include, but are not limited to, systemic hypertension, angina, stroke, retinal vascular diseases, claudication, Raynauds disease, diabetes, and pulmonary hypertension.
- the effects of the compounds of this invention on intraocular pressure are also provided in the following tables.
- the compounds were prepared at the said concentrations in a vehicle comprising 0.1% polysorbate 80 and 10 mM TRIS base. Dogs were treated by administering 25 ⁇ l to the ocular surface, the contralateral eye received vehicle as a control. Intraocular pressure was measured by applanation pneumatonometry. Dog intraocular pressure was measured immediately before drug administration and at 6 hours thereafter.
- the compounds of the invention may also be useful in the treatment of various pathophysiological diseases including acute myocardial infarction, vascular thrombosis, hypertension, pulmonary hypertension, ischemic heart disease, congestive heart failure, and angina pectoris, in which case the compounds may be administered by any means that effect vasodilation and thereby relieve the symptoms of the disease.
- administration may be by oral, transdermal, parenterial, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes.
- the compounds of the invention may be used alone, or in combination with other of the known vasodilator drugs.
- the compounds of the invention may be formulated into an ointment containing about 0.10 to 10% of the active ingredient in a suitable base of, for example, white petrolatum, mineral oil and petroatum and lanolin alcohol.
- suitable bases will be readily apparent to those skilled in the art.
- the pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, by means of conventional dissolving or suspending the compounds, which are all either water soluble or suspendable.
- the pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules make of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain the active compounds in liquid form that may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are preferably dissolved or suspended in suitable liquids, such as in buffered salt solution.
- stabilizers may be added.
- the pharmaceutical preparations may contain suitable excipients to facilitate the processing of the active compounds into preparations that can be used pharmaceutically.
- suitable excipients to facilitate the processing of the active compounds into preparations that can be used pharmaceutically.
- pharmaceutical preparations for oral use can be obtained by adhering the solution of the active compounds to a solid support, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as inders such as starch, paste using for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- fillers such as sugars, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as inders such as starch, paste using for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl
- disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, crosslinked polyvinyl pyrrolidone, agar, or algenic acid or a salt thereof, such as sodium alginate.
- Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable coatings which if desired, are resistant to gastric juices.
- concentrated sugar solutions may be used, which may optionally containing gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used.
- Dye stuffs or pigments may be added to the tables or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Suitable formulations for intravenous or parenteral administration include aqueous solutions of the active compounds.
- suspensions of the active compounds as oily injection suspensions may be administered.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, soribitol, and/or dextran.
- the suspension may also contain stabilizers.
Abstract
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I:
wherein wavy line attachments indicate either the alpha (α) or beta (β) configuration; dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, R1 is hydrogen or a lower alkyl radical having up to six carbon 20 atoms, X is selected from the group consisting of —OR1, —N(R1)2 and —N(R5)SO2R6, wherein R5 represents hydrogen or CH2OR6 and R6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical, e.g. a fluoro substituted lower alkyl radical; Y is ═O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.
Description
- This patent application is a continuation of Ser. No. 10/021,485, filed Oct. 29, 2001, which is a continuation of application Ser. No. 09/795,982, which was filed on Feb. 28, 2001 now U.S. Pat. No. 6,310,087; which is a continuation of U.S. Ser. No. 09/523,880, which was filed on Mar. 13, 2000, now U.S. Pat. No. 6,204,287; which is a continuation of Ser. No. 09/295,003, which was filed on Apr. 20, 1999, now U.S. Pat. No. 6,037,364; which is a continuation of U.S. Ser. No. 09/185,403 which was filed on Nov. 3, 1998, now U.S. Pat. No. 5,972,991; which is a continuation-in-part of U.S. Ser. No.08/726,921, which was filed on Oct. 7, 1996, now U.S. Pat. No. 5,834,498; which is continuation-in-part of U.S. Ser. No. 08/605,567 filed on Feb. 22, 1996, now U.S. Pat. No. 5,688,819; which is a continuation-in-part of U.S. Ser. No. 08/371,339 which was filed on Jan. 11, 1995, now U.S. Pat. No. 5,607,978; which is a continuation of U.S. Ser. No. 08/154,244 which was filed Nov. 18, 1993, now abandoned; which is a divisional of U.S. Ser. No. 07/948,056 filed Sep. 21, 1992, now U.S. Pat. No. 5,352,708.
- 1. Field of the Invention
- The present invention relates to cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives which may be substituted in the 1-position with hydroxyl, alkyloxy, amino and amido groups, e.g. 1-OH cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives. These compounds are potent ocular hypotensive and are particularly suited for the management of glaucoma.
- 2. Description of Related Art
- Ocular hypotensive agents are useful in the treatment of a number of various ocular hypertensive conditions, such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts.
- Glaucoma is a disease of the eye characterized by increased intraocular pressure. On the basis of its etiology, glaucoma has been classified as primary or secondary. For example, primary glaucoma in adults (congenital glaucoma) may be either open-angle or acute or chronic angle-closure. Secondary glaucoma results from pre-existing ocular diseases such as uveitis, intraocular tumor or an enlarged cataract.
- The underlying causes of primary glaucoma are not yet known. The increased intraocular tension is due to the obstruction of aqueous humor outflow. In chronic open-angle glaucoma, the anterior chamber and its anatomic structures appear normal, but drainage of the aqueous humor is impeded. In acute or chronic angle-closure angle-closure glaucoma, the anterior chamber is shallow, the filtration angle is narrowed, and the iris may obstruct the trabecular meshwork at the entrance of the canal of Schlemm. Dilation of the pupil may push the root of the iris forward against the angle, and may produce pupilary block and thus precipitate an acute attack. Eyes with narrow anterior chamber angles are predisposed to acute angle-closure glaucoma attacks of various degrees of severity.
- Secondary glaucoma is caused by any interference with the flow of aqueous humor from the posterior chamber into the anterior chamber and subsequently, into the canal of Schlemm. Inflammatory disease of the anterior segment may prevent aqueous escape by causing complete posterior synechia in iris bombe, and may plug the drainage channel with exudates. Other common causes are intraocular tumors, enlarged cataracts, central retinal vein occlusion, trauma to the eye, operative procedures and intraocular hemorrhage.
- Considering all types together, glaucoma occurs in about 2% of all persons over the age of 40 and may be asymptotic for years before progressing to rapid loss of vision. In cases where surgery is not indicated, topical b-adrenoreceptor antagonists have traditionally been the drugs of choice for treating glaucoma.
- Certain eicosanoids and their derivatives have been reported to possess ocular hypotensive activity, and have been recommended for use in glaucoma management. Eicosanoids and derivatives include numerous biologically important compounds such as prostaglandins and their derivatives. Prostaglandins can be described as derivatives of prostanoic acid which have the following structural formula:
- Various types of prostaglandins are known, depending on the structure and substituents carried on the alicyclic ring of the prostanoic acid skeleton. Further classification is based on the number of unsaturated bonds in the side chain indicated by numerical subscripts after the generic type of prostaglandin [e.g. prostaglandin E1 (PGE1), prostaglandin E2 (PGE2)], and on the configuration of the substituents on the alicyclic ring indicated by α or β[[e.g. prostaglandin F2α (PGF2α)].
- Prostaglandins were earlier regarded as potent ocular hypertensives, however, evidence accumulated in the last decade shows that some prostaglandins are highly effective ocular hypotensive agents, and are ideally suited for the long-term medical management of glaucoma (see, for example, Bito, L. Z.Biological Protection with Prostaglandins, Cohen, M. M., ed., Boca Raton, Fla., CRC Press Inc., 1985, pp. 231-252; and Bito, L. Z., Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S. M. and Neufeld, A. H. eds., New York, Grune & Stratton, 1984, pp. 477-505. Such prostaglandins include PGF2α, PGF1α, PGE2, and certain lipid-soluble esters, such as C1 to C2 alkyl esters, e.g. 1-isopropyl ester, of such compounds.
- Although the precise mechanism is not yet known experimental results indicate that the prostaglandin-induced reduction in intraocular pressure results from increased uveoscleral outflow [Nilsson et. al.,Invest. Ophthalmol. Vis. Sci. (suppl), 284 (1987)].
- The isopropyl ester of PGF2α has been shown to have significantly greater hypotensive potency than the parent compound, presumably as a result of its more effective penetration through the cornea. In 1987, this compound was described as “the most potent ocular hypotensive agent ever reported” [see, for example, Bito, L. Z., Arch. Ophthalmol. 105, 1036 (1987), and Siebold et.al.,
Prodrug 5 3 (1989)]. - Whereas prostaglandins appear to be devoid of significant intraocular side effects, ocular surface (conjunctival) hyperemia and foreign-body sensation have been consistently associated with the topical ocular use of such compounds, in particular PGF2α and its prodrugs, e.g., its 1-isopropyl ester, in humans. The clinical potentials of prostaglandins in the management of conditions associated with increased ocular pressure, e.g. glaucoma are greatly limited by these side effects.
- In a series of co-pending United States patent applications assigned to Allergan, Inc. prostaglandin esters with increased ocular hypotensive activity accompanied with no or substantially reduced side-effects are disclosed. The co-pending U.S. Ser. No. 596,430 (filed Oct. 10, 1990), relates to certain 11-acyl-prostaglandins, such as 11-pivaloyl, 11-acetyl, 11-isobutyryl, 11-valeryl, and 11-isovaleryl PGF2α. Intraocular pressure reducing 15-acyl prostaglandins are disclosed in the co-pending application U.S. Ser. No. 175,476 (filed Dec. 29, 1993). Similarly, 11,15-9,15 and 9,11-diesters of prostaglandins, for example 11,15-dipivaloyl PGF2α are known to have ocular hypotensive activity. See the co-pending patent applications U.S. Ser. No. Nos. 385,645 (filed Jul. 07, 1989, now U.S. Pat. Nos. 4,994,274), 584,370 (filed Sep. 18, 1990, now U.S. Pat. Nos. 5,028,624) and 585,284 (filed Sep. 18, 1990, now U.S. Pat. No. 5,034,413). The disclosures of all of these patent applications are hereby expressly incorporated by reference.
-
- wherein the wavy segments represent an α or β bond, dashed lines represent a double bond or a single bond, R is a substituted heteroaryl radical, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, and
- —N(R5)SO2R6, wherein R5 represents hydrogen or CH2OR6 and R6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical, e.g. a fluoro substituted lower alkyl radical; Y is ═O or represents 2 hydrogen radicals, and 1, 9, 11 or 15 esters thereof.
- In a further aspect, the present invention relates to an ophthalmic solution comprising a therapeutically effective amount of a compound of formula (I), wherein the symbols have the above meanings, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application. In particular, the substituents on the heteroaryl radical may be selected from the group consisting of lower alkyl, e.g. C1 to C6 alkyl; halogen, e.g. fluoro, chloro and bromo; trifluoromethyl (CF3); COR1, e.g. COCH3; COCF3; SO2NR1, e.g. SO2NH2; NO2; CN; etc.
- In a still further aspect, the present invention relates to a pharmaceutical product, comprising
- a container adapted to dispense its contents in a metered form; and
- an ophthalmic solution therein, as hereinabove defined.
- Finally, certain of the compounds represented by the above formula, disclosed below and utilized in the method of the present invention are novel and unobvious.
- FIG. 1 is a schematic of the chemical synthesis of certain 1-carboxylic acid compounds of the invention specifically disclosed as Example 4(a)-(v) below.
- FIG. 2 is a schematic of the chemical synthesis of certain δ-substituted thienyl 1-carboxylic acid compound of the invention specifically disclosed as Examples 6 and 6(a), below.
- FIG. 3 is a schematic of the chemical synthesis of certain 1-amido compounds of the invention specifically disclosed as Examples 8(p)-(q), below.
- FIG. 4 is a schematic of the chemical synthesis of certain -substituted thienyl 1-carboxylic acid compounds.
- FIG. 5 is a schematic of the chemical synthesis of δ-substituted furanyl-1-carboxylic acid compounds specifically disclosed as Example 15.
- The present invention relates to the use of cyclopentane heptan(ene)oic acid, 2-heteroaryl alkenyl derivatives as therapeutic agents, e.g. as ocular hypotensives. The compounds or derivatives used in accordance with the present invention are encompassed by the above structural formula I:
-
- wherein the substituents and symbols are as hereinabove defined. The dotted lines on bonds between
carbons 5 and 6 (C-5) andcarbons 13 and 14 (C-13) indicate a single or double bond. If two solid lines are used at C-5, or C-13, it indicates a specific configuration for that double bond. Hatched lines used at position C-8, C-9 and C-11 indicate the α configuration. A triangle at position C-12 represents β orientation. A more preferred group of the compounds of the present invention includes compounds that have the following structural formula III: -
- R3 and R4 forms a condensed aryl ring. Preferably, when X is —N(R1)2, Y is ═O.
- More preferably, at least one of R2, R3 or R4 are independently selected from the group consisting of chloro, bromo and lower alkyl. In one aspect of the invention, at least one of R2, R3 or R4 is chloro or bromo, and more preferably at least one of R2, R3 or R4 is bromo or at least two of R2, R3 or R4 are chloro. In another aspect of this invention, at least one of R2, R3 or R4 is ethyl, propyl, or butyl.
-
- Preferably R6 is methyl, ethyl or trifluoromethyl.
-
- In the above formulae, the substituents and symbols are as hereinabove defined and R5 is hydrogen or methyl.
- The above compounds of the present invention may be prepared by methods that are known in the art or according to the working examples below. The compounds, below, are especially preferred representative of the compounds of the present invention.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)-thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid
- 7-[3α,5α,-Dihydroxy-2-(3α-hydroxy-5-(4-(2-methyl)-thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-chloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(4-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2,5-dichloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-chloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-benzothienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-benzofuranyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-furanyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-furanyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-thiazolyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3β-hydroxy-5-(2-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2,5-dichloro)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3β-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-methoxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3β-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3,4 dibromo)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(5-iodo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(4-bromo, 5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3,5-dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3,4 dibromo-5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(4 chloro-5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(2 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-iodo)2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-methyl 4 bromo)2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3,4 dibromo )2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-methyl, 4,5 dibromo)-2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-methyl, 4 chloro)-2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide.
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(5-methyl 2-thienyl)1-E-pentenyl)cyclopentyl]-5Z-heptenamide.
- A pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered. Of particular interest are salts formed with inorganic ions, such as sodium, potassium, calcium, magnesium and zinc.
- Pharmaceutical compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable acid addition salt thereof, as an active ingredient, with conventional ophthalmically acceptable pharmaceutical excipients, and by preparation of unit dosage forms suitable for topical ocular use. The therapeutically efficient amount typically is between about 0.0001 and about 5% (w/v), preferably about 0.001 to about 1.0% (w/v) in liquid formulations.
- For ophthalmic application, preferably solutions are prepared using a physiological saline solution as a major vehicle. The pH of such ophthalmic solutions should preferably be maintained between 6.5 and 7.2 with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.
- Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A preferred surfactant is, for example, Tween 80. Likewise, various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.
- Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.
- Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
- In a similar vein, an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
- Other excipient components which may be included in the ophthalmic preparations are chelating agents. The preferred chelating agent is edentate disodium, although other chelating agents may also be used in place or in conjunction with it.
- The ingredients are usually used in the following amounts:
Ingredient Amount (% w/v) active ingredient about 0.001-5 preservative 0-0.10 vehicle 0-40 tonicity adjustor 1-10 buffer 0.01-10 pH adjustor q.s. pH 4.5-7.5 antioxidant as needed surfactant as needed purified water as needed to make 100% - The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.
- The ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate the application to the eye.
- Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution.
- The invention is further illustrated by the following non-limiting Examples, which are summarized in the reaction schemes of FIGS. 1 through 4, wherein the compounds are identified by the same designator in both the Examples and the Figures.
-
Compound 4a - 7-[3α,5α,-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid
- Step 1: Preparation of Enone 2a
- To a suspension of sodium hydride (36 mg, 1.50 mmol) in THF (4.5 mL) cooled to 0° C. was added dimethyl 4-(3-(2-methyl)thienyl)-2-oxo-butylphosphonate(414 mg, 1.50 mmol) in THF (3.0 mL). After 0.25 h a solution of the aldehyde 1 (438 mg, 1.00 mmol) in THF (3.0 mL) was added and the reaction was allowed to slowly warm to 23° C. over a period of 8 h. The reaction solution was quenched with saturated aqueous NH4Cl and extracted w/EtOAc. The aqueous phase was made slightly acidic before extraction with EtOAc. The combined organics were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Flash column chromatography (silica gel, 2:1 hex/EtOAc) gave 544 mg (93%) of the enone 2a.
- Step 2: Preparation of Alcohol 3a
- Sodium tetrahydriodoborate (35 mg, 0.93 mmol) was added to a solution of the enone 2a (544 mg, 0.93 mmol) in MeOH(4.5 mL) at 0° C. After 2 h the solvent was removed in vacuo and the residue was stirred with 1N NaOH/EtOAc. The organic portion was separated, dried (MgSO4), filtered and concentrated in vacuo. The 3a-alcohol was separated by flash column chromatography or HPLC (silica gel, 3:1 Hex/EtOAc).
- Step 3: Preparation of 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- A solution of alcohol 3a and pyridinium p-toluene sulfonate (116 mg, 0.462 mmol) in MeOH(4.5mL) was heated at 40° C. for 4 h. The solvent was removed in vacuo and the residue was diluted with EtOAc followed by washing with 1N HCl, saturated aqueous NaHCO3 and brine. The organic portion was dried (MgSO4), filtered and concentrated in vacuo.
- The residue was diluted with THF (0.78 mL) and lithium hydroxide (0.39 mL of a 0.5N solution in H2O, 0.194 mmol) was added. After 16 h the reaction was acidified with IN HCl and extracted with EtOAc The organic portion was washed with brine, dried (MgSO4), and concentrated in vacuo to give 37.6 mg of the
free acid 4a. - The title compound was identified by the following NMR spectrum.
-
- By methods described for
compound 4a, steps 1 through 3, the following compounds were prepared. (The compounds below are also identified by their NMR spectra.) - Compound 4b
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-(5-methyl)thienyl)-2-oxo-butylphosphonate afforded 26 mg of free acid 4b.
-
- Compound 4c
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(5-methyl)thienyl)-1E-pentynyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(3-(2-methyl)thienyl)-2-oxo-butyl phosphonate afforded 25 mg of free acid 4c.
-
- Compound 4d
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-chloro)thienyl)-1E-pentynyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(3-(2-chloro)thienyl)-2-oxo-butylphosphonate afforded 25 mg of free acid 4d.
-
- Compound 4e
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(4-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-(4-bromo)thienyl)-2-oxo-butylphosphonate afforded 10 mg of free acid 4e.
-
- Compound 4f
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-(5-bromo)thienyl)-2-oxo-butylphosphonate afforded 50 mg of free acid 4f.
-
- Compound 4g
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2,5-dichloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(3-(2,5-dichloro)thienyl)-2-oxo-butylphosphonate afforded 18 mg of free acid 4g.
-
- Compound 4h
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-chloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-(3-chloro)thienyl)-2-oxo-butylphosphonate afforded 10 mg of free acid 4h.
-
- Compound 4i
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-benzothienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-benzothienyl)-2-oxo-butylphosphonate afforded 22 mg of free acid 4i.
-
- Compound 4j
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-benzofuranyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-benzofuranyl)-2-oxo-butylphosphonate afforded 30.5 mg of free acid 4j.
-
- Compound 4k
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-furanyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(3-furanyl)-2-oxo-butylphosphonate afforded 10.1 mg of free acid 4k.
- 1H NMR (300 MH2, CDCl3) δ12.0(brs, 1H), 7.35 (d, J=1.7 Hz, 1H), 7.23(s, 1H), 6.28 (d, J=1.7 Hz, 1H), 5.34-5.64(m, 4H), 4.15-4.20(m, 2H), 3.90-3.94 (m, 1H), 3.70 (brs, 3H), 2.09-2.52 (m, 12H), 1.40-1.88 (m, 4H).
- Compound 4l
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-furanyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-furanyl)-2-oxo-butylphosphonate afforded 33.3 mg of free acid 4l.
-
- Compound 4m
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-thiazolyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-thiazolyl)-2-oxo-butylphosphonate afforded 32.2 mg of free acid 4m.
-
- Compound 4n
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-thienyl)-2-oxo-butylphosphonate afforded 15.0 mg of free acid 4n.
-
- Compound 4o
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- The 3β-isomer of 3n was isolated from the reaction mixture obtained in
step 2 during preparation of 4n and subjected to step 3 to afford 14.3 mg of free acid 4o. -
- Compound 4p
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(3-thienyl)-2-oxo-butylphosphonate afforded 9.6 mg of free acid 4p. While this compound is not a substituted heteroaryl derivative within the scope of general Formula I, above, it represents another aspect of this invention in view of its excellent ability to lower intraocular pressure as shown below.
-
- Compound 4q
- 7-[3α,5α-Dihydroxy-2-(3β-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- The 3β-isomer of 3p was isolated from the reaction mixture obtained in
step 2 during preparation of 4p and subjected to step 3 to afford 36.2 mg of free acid 4q. -
- Compound 4r
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-ethyl)thienyl-1E-pentenyl)cyclopentyl-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2(5-ethyl)thienyl)2-oxo-butylphosphonate will result in the free acid 4r.
- Compound 4s
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-butyl)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-(5-butyl)thienyl)2-oxo-butylphosphonate will result in the free acid 4s.
- Compound 4t
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-propyl)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-(5-propyl)thienyl)2-oxo-butylphosphonate will result in the free acid 4t.
- Compound 4u
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-methoxy)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedures described above for 4a, the use of dimethyl 4-(2-(5-methoxy)thienyl)2-oxo-butylphosphonate will result in the free acid 4u.
- Compound 4v
- 7-[3α,5α-Dihydroxy-2-(3β-hydroxy-5-(2-thiazolyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- The 3β isomer of 3m was isolated from the reaction mixture obtained in
Step 2 during preparation of 4m and subjected toStep 3 to afford the free acid 4v. - Compound 4w
- 7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3-chloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the process described above for 4a, the use of dimethyl 4-(2-(3-chloro)thienyl)2-oxo-butyl phosphonate will result in the free acid 4w.
- Compound 4x
- 7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3,4 dibromo)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedure described above for 4a, the use of dimethyl 4-(2-(3,4 dibromo)thienyl 2-oxo-butyl phosphonate afforded the free acid 4x
- Compound 4y
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(5-iodo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedure described above for 4a, the use of dimethyl 4-(2-(7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(5-iodo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid)thienyl afforded the free acid 4y
- Compound 4z
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(4-bromo, 5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedure described above for 4a, the use of dimethyl 4-(2-(7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(4-bromo, 5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid)thienyl afforded the free acid 4z
- Compound 4aa
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3,5-dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedure described above for 4a, the use of dimethyl 4-(2-(7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3,5-dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid)thienyl afforded the free acid 4aa
- Compound 4ab
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3,4 dibromo-5 methyl )thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedure described above for 4a, the use of dimethyl 4-(2-(7-[3a,5a-Dihydroxy-2-(3-hydroxy-5-(2-(3,4 dibromo-5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid)thienyl afforded the free acid 4ab
- Compound 4ac
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(4 chloro-5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedure described above for 4a, the use of dimethyl 4-(2-(7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(4 chloro-5 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid)thienyl afforded the free acid 4ac
- Compound 4ad
- (7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(3 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- According to the procedure described above for 4a, the use of dimethyl 4-(2-((7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(2-(2 methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid)thienyl afforded the free acid 4 ad
-
Compound 6 - 7-[3α,5α-Dihydroxy-2-(3α-methoxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- Alcohol (400 mg, 0.694 mmol) obtained in
step 2 of preparation of 4p was treated with silver triflate (803 mg, 3.12 mmol), 2,6-di-t-butyl-pyridine (0.89 mL, 3.98 mmol) and iodomethane (0.21 mL, 3.4 mmol) in CH2Cl2 (11 mL) at 0° C. After 12 h the reaction mixture was filtered through celite, concentrated in vacuo and purified by flash column chromatography to give the 3α-methoxy product 5. Further subjection of 5 to the procedures described above instep 3 of preparation of 4a provided 41.2 mg offree acid 6. -
- Compound 16a
- 7-[3α,5α-Dihydroxy-2-(3αmethoxy-5-(2-(3,4-dibromo)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenoic acid (16a)
- Methyl triflate (25 μL, 0.22 mmol) was added to a solution of 2,6-di-t-butylpyridine (60 μL, 0.27 mmol) and the corresponding alcohol prepared as above for alcohol 3a (54 mg, 0.074 mmol) in CH2,Cl2 (0.4 mL) at 23° C. After 12 h the reaction was diluted with CH2Cl2, and washed with 1N HCl, saturated aqueous Na2HCO3 and brine, then dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 3:1 hex/EtOAc) to furnish 50 mg (90%) of the methyl ester.
- A solution of said methyl ester (50 mg, 0.67 mmol) and pyridinium p-toluenesulfonate (23 mg, 0.92 mmol) in MeOH (0.2 mL) was stirred at 40° C. for 12 h. After allowing the reaction to cool to room temperature the solvent was removed in vacuo. The residue was diluted with EtOAc and washed with 1N HCl, saturated aqueous NaHCO3, and brine. The organic portion was then dried over MgSO4, filtered and the filtrate concentrated in vacuum. Purification of the residue by flash column chromatography (silica gel, 1:1 hex/EtOAc) gave 33 mg (74%) of the 15-methoxy ester.
- Lithium hydroxide (0.26 mL of a 0.5 N solution in H2O, 0.13 mmol) was added to a solution of the methoxy ester (33 mg, 0.057 mmol) in THF (0.52 mL) at 23° C. After 12 h the reaction mixture was acidified with 1N HCl and extracted with EtOAc. The organic portion was washed twice with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by elution through a Sep-Pak cartridge (silica gel, 100% EtOAc followed by 9:1 CH2Cl2/MeOH) to afford 20 mg (62%) of the title compound 16a.
- Compound 16b
- 7-[3α,5α-Dihydroxy-2-(3α-methoxy-5-(5-(3-bromo-2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid (16b)
- In accordance with the procedures described above for the preparation of 15-methoxy acid 16a, the use of alcohol provided 25 mg of title compound 16a.
- Compound 16c
- 7-[3α,5α-Dihydroxy-2-(3(α-methoxy-5-(2-(3,5.dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid (16c)
- In accordance with the procedures described above for the preparation of 15-methoxy acid 16a, the use of the corresponding alcohol provided 14 mg of title compound 16c.
- Compound 16d
- 7-[3α,5α-Dihydroxy-2-(3α-methoxy-5-(5-(3,4-dibromo-2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid (16d)
- In accordance with the procedures described above for the preparation of 15-methoxy acid 16a, the use of the corresponding alcohol provided 21 mg of title compound 16d.
- Compound 16e
- 7-[3α,5α-Dihydroxy-2-(3α,-methoxy-5-(5-(3-chloro-2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid (16e)
- In accordance with the procedures described above for the preparation of 15-methoxy acid 16a, the use of the corresponding alcohol provided 19 mg of title compound 16e.
- Compound 16f
- 7-[3α,5α-Dihydroxy-2-(3α-methoxy-5-(2-(3-methyl)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenoic acid (16f)
- In accordance with the procedures described above for the preparation of 15-methoxy acid 16a, the use of the corresponding alcohol provided 11 mg of title compound 16f.
- Compound 16g
- 7-[3α,5α-Dihydroxy-2-(3α-methoxy-5-(5-(2-bromo-3-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid (16g)
- In accordance with the procedures described above for the preparation of 15-methoxy acid 16a, the use of the corresponding alcohol provided 12 mg of title compound 16g.
- Compound 8p
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- The 3α-alcohol 3p, isolated from
step 2 during preparation of 4p, was deprotected with pyridinium p-toluenesulfonate in MeOH at 45° C. for 4 h and after the usual work-up gavetriol 7p. - A mixture of 7p and ammonium chloride in liquid ammonia was heated to 55° C. for 48 h in a sealed tube. The tube was recooled to −70° C., vented, and then allowed to warm to room temperature on its own accord. The residue was dissolved in 1:1 EtOAc/H2O. The organic portion was separated, dried (MgSO4), filtered and concentrated in vacuo. Flash column chromatography (silica gel, 9:1 CH2Cl2/MeOH) gave 10.9 mg of the title compound 8p.
-
- Compound 8q
- 7-[3α,5α-Dihydroxy-2-(3β-hydroxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- According to the procedures described for preparation of 8p the 3β-alcohol 3g was converted to the title compound 8q.
-
- Compound 8r
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2,5-dichloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- According to the procedures described for preparation of 8p the alcohol 3r was converted to the title compound 8r.
-
- In a method analogous to the method of preparation of compounds 8p and 8q, the following compounds were prepared:
- Compound 8s
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3,4 dibromo)2thienyl)-1-E pentyl)cyclopentyl]-5Z-heptenamide
- Compound 8t
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-iodo)2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide
- Compound 8u
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-methyl 4 bromo)2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide
- Compound 8v
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3,4 dibromo )2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide
- Compound 8w
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-methyl, 4,5 dibromo)-2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide
- Compound 8x
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-methyl, 4 chloro)-2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide
- Compound 8y
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(5-methyl 2-thienyl)1-E pentyl)cyclopentyl]-5Z-heptenamide
- Compound 8z
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-methyl)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenamide 8z
- Compound 8aa
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(5-(2-iodo)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenamide (8aa) (8aa)
- Compound 8ab
- 7-[3α,5α-Dihydroxy-2 (3α-hydroxy-5-(5-(3-bromo-2-methyl)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenamide (8ab)
- Compound 8ac
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3,5-dibromo)tbienyl)-1E-pentenyl)-cyclopentyl]-5Z-heptenamide (8ac)
- Compound 8ad
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(5-(3,4-dibromo-2-methyl)-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide (8ad)
- Compound 8ae
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(5-(3-chloro-2-methyl)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenamide (8ae)
- Compound 8af
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-methyl)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenamide (8af)
-
Compound 13 - 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-thienyl)pentyl)cyclopentyl]-5Z-heptenoic acid.
- Step 1: Preparation of Alcohol
- To a suspension of sodium hydride 271 mg (11.30 mmol) in THF (21 mL) cooled to 0° C. was added a solution of dimethyl 4-(3-thienyl)-2-oxo-butylphosphonate (2.96 g, 11.30 mmol) in THF (10 mL). After stirring for 0.5 h a solution of aldehyde 9 (2.80 g, 10.28 mmol) in THF (10 mL) was added dropwise. The reaction was allowed to warm to room temperature and stirred for a total of 12 h before quenching with saturated aqueous NH4Cl. The mixture was extracted with EtOAc and the organic portion was washed with saturated aqueous NaHCO3, brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 1:1 hex/EtoAc) to afford 3.98, (95%) of enone.
- Immediately, a solution of the enone (3.98 g, 9.75 mmol) in MeOH (22 mL) was cooled to 0° C. and sodium tetrahydridoborate (369 mg, 9.75 mmol) was added. After 2 h the reaction was quenched with saturated aqueous NH4Cl and extracted with EtOAc. The organic portion was washed with brine, dried (MgSO4) filtered and concentrated in vacuo. Purification by HPLC (Waters Partisil-10, 1:1 hex/EtOAc) afforded 1.30 g (33%) of the α-
alcohol 10. -
- Step 2: Preparation of Bis-
Silyl Ether 11 - Potassium carbonate (523 mg, 3.78 mmol) was added to a solution of benzoate 10 (1.3 g, 3.15 mmol) in MeOH(6.5 mL). After 16 h the reaction solvent was removed in vacuo and the residue was dissolved in EtOAc/saturated aqueous NH4Cl. The organic portion was washed with brine, dried (MgSO4), filtered and concentrated in vacuo.
- The residue was dissolved in THF (6.5 mL) and triphenylphosphine rhodium chloride (400 mg) was added. The solution was degassed and purged under an atmosphere of hydrogen gas at 40-45 psi. After 16 h the reaction was concentrated in vacuo, and the residue purified by flash column chromatography (silica gel, 3:1 hex/EtOAc) to afford the apparent saturated diol after evaporation of the solvents.
- The apparent diol was dissolved in CH2Cl2 (6.5 mL) and 2,6-lutidine (2.0 mL, 16.5 mmol) was added followed by t-butyldimethylsilyl triflate (3.0 mL, 13.2 mmol). The reaction was quenched with saturated aqueous NaHCO3 and washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Flash column chromatography (9:1 hex/EtOAc) gave 1.29 g (94%) of the bis-
TBDMS ether 11. -
- Step 3: Preparation of
Ester 12 - Lactone 11 (170 mg, 0.315 mmol) was dissolved in CH2Cl2 (1.0 mL) and cooled to −70° C. Dibal-H(0.47 mL of a 1.0 M solution in CH2Cl2, 0.47 mmol) was added. After 2 h the reaction was quenched with MeOH, allowed to warm to room temperature, and extracted with CH2Cl2. The organic portion was dried (Na2SO4), filtered and concentrated in vacuo to give the lactol as a clear, viscous oil.
- To a suspension of (4-carboxybutyl)triphenylphosphonium bromide (558 mg, 1.26 mmol) in THF (2.5mL) was added potassium bis (trimethylsilyl)amide(503 mg, 2.52 mmol) at 0° C. After 0.5 h the solution was cooled to −70° C. and a solution of the lactol in THF (2.5 mL) was added. The reaction was allowed to warm to room temperature on its own accord, quenched with saturated aqueous NH4Cl, and extracted with EtOAc. The organic portion was washed with saturated aqueous NaHCO3, brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was diluted with Et2O and excess diazomethane in Et2O was added until the reaction solution persisted yellow. Evaporation of the solvent gave 140 mg (70%) of
ester 12. -
- Step 4:
Preparation Carboxylic Acid 13 - To a solution of bis-TBDMS ether 12 (25 mg, 0.040 mmol) in THF (0.24 mL) was added Bu4NF (0.12 mL of a 1.0M solution in THF, 0.12 mmol). After 16 h the reaction was concentrated in vacuo and purified by flash column chromatography (silica gel, 3:1 hex/EtOAc) to yield 13.0 mg (79%) of the triol.
- Lithium hydroxide (0.15 mL of a 0.5N solution in H2O, 0.073 mmol) was added to a solution of the ester (13.0 mg, 0.0316 mmol) in THF (0.3 mL). After 16 h the reaction was acidified with 1N HCl and extracted with EtOAc. The organic portion was dried (MgSO4), filtered and concentrated in vacuo to give 7.0 mg (56%) of
free acid 13. -
-
Compound 15 - 7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(3-furanyl)pentyl)cyclopentyl]-5Z-
heptenoic acid 15. - Step 1: Preparation of
ketone 14. - A mixture of the enone (137 mg, 0.245 mmol) obtained in
step 2 of preparation of 4k above, Aliquat 336 (34 μL, 0.074 mmol), sodium dithionite (384.7 mg, 2.21 mmol) and sodium bicarbonate (371.3 mg, 4.42 mmol) in benzene: H2O (1:1, 6.0 mL) was heated to 75° C. for 1.5 h. The reaction mixture was allowed to cool to room temperature, was diluted with EtoAc, and was washed with H2O and brine. The organic portion was dried (MgSO4), filtered and the filtrate was concentrated in vacuo. Purification by flash column chromatography (silica gel, 4:1 hex/EtOAc) gave 113.3 mg (83%) of theketone 14. - Step 2: Preparation of 7-[3α,5α-Dihydroxy-2-(3-hydroxy-5-(3-furanyl)pentyl)cyclopentyl]-5Z-
heptenoic acid 15. - Sodium tetrahydridoborate (14.2 mg, 0.375 mmol) was added to a solution of the ketone (210 mg, 0.375 mmol) in MeOH (3.0 mL) cooled to 0° C. After 30 minutes the reaction was quenched with saturated aqueous ammonium chloride and allowed to warm to room temperature. The mixture was extracted with Et2O and the organic portion was dried (MgSO4), filtered and concentrated in vacuo.
- The residue was diluted with MeOH (3.0 mL) and pyridinium p-toluene sulfonate (141 mg, 0.562 mmol) was added. After heating to 45° C. for 16 h the reaction was concentrated in vacuo, diluted with EtOAc and washed with 1 N HCl, saturated aqueous sodium bicarbonate, brine, dried (MgSO4), filtered and concentrated in vacuo. Flash column chromatography (silica gel, 2:1 hex/EtOAc) followed by 100% EtOAc) gave 123 mg (83%) of a mixture of alcohols which were homogenous by TLC.
- The mixture of alcohols (52.3 mg, 0.132 mmol) was diluted with THF (1.0 mL) and lithium hydroxide (0.53 mL of a 0.5 N solution in H2O, 0.265 mmol) was added. After 16 h the reaction was acidified with 1 N HCl and extracted with EtOAc. The organic portion was washed with brine, dried (MgSO4) filtered and concentrated in vacuo to afford 44.6 mg (89%) of
free acid 15. -
- Compound 16a
- Isopropyl 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-methyl)thienyl)-IE-pentenyl)cyclopentyl]-5Z-heptenoate (16a)
- A solution of free acid 5 g (17.5 mg, 0.043 mmol), 2-iodopropane (21 μL, 0.22 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (20 μL, 0.13 mmol) in acetone (0.1 mL) was stirred at 23° C. for 12 h. The reaction mixture was concentrated in vacuo and the residue was purified by flash column chromatography (silica gel, 3:1 EtOAc/hexane) to yield 15 mg (77%) of the isopropyl ester 10 g.
- By analoguous methods of synthesis, the following compounds of the invention are prepared:
- Compound 17a
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-cyano)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- Compound 17b
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-cyano)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 17c
- Isopropyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-cyano)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoate.
- Compound 18a
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-fluoro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid.
- Compound 18b
- 7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(3-fluoro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 19a
- N-Methylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 19b
- N-Ethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 19c
- N-Trifluoromethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 20a
- N-Methylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-chloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 20b
- N-Ethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-chloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 20c
- N-Trifluoromethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-chloro)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 21a
- N-Methylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-iodo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 21b
- N-Ethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-iodo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 21c
- N-Trifluoromethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-iodo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 22a
- N-Methylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 22b
- N-Ethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 22c
- N-Trifluoromethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 23a
- N-Methylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 23b
- N-Ethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 23c
- N-Trifluoromethylsulfonyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 24
- N-Methylsulfonyl-N-acetylmethyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Compound 25
- N-Methylsulfonyl-N-pivaloylmethyl-7-[3α,5α-Dihydroxy-2-(3α-hydroxy-5-(2-(5-bromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamide.
- Certain of the sulfonyl compounds, above, may be synthesized according to the procedures disclosed in U.S. patent application Ser. No. 09/880,272 filed on Jun. 13, 2001 in the names of David W. Old and Robert M. Burk, which is hereby incorporated by reference in its entirety.
- Certain of the above compounds were tested for activity in the various in vitro assays described below and the results are reported in Tables below.
- Activity at different prostanoid receptors was measured in vitro in isolated smooth muscle preparations. FP-activity was measured as contraction of the isolated feline iris sphincter. EP1-activity was measured as contraction of the longitudinal smooth muscle of the isolated guinea pig ileum. EP3-activity was measured as inhibition of the twitch response induced by electrical field stimulation in the isolated guinea pig was deferens and as contraction of the longitudinal smooth muscle of the isolated chick ileum. Activity was also measured as relaxation of smooth muscle of isolated rabbit jugular vein a preparation which appears to contain a unique PGF2α-sensitive receptor provisionally termed FPVASC. TP-vasoconstrictor activity was measured as contraction of rings of the isolated rat thoracic aorta. Effects on platelets from healthy human donors were measured by incubating platelet-rich plasma with the compounds described herein. Inhibition of aggregation was determined by the ability of the compounds described herein to inhibit platelet aggregation in platelet-rich plasma induced by 20 μM ADP.
- In addition to stimulating the FP receptor associated with the cat iris, several examples also stimulated the EP3 receptor. Compounds with agonist activity at EP3 receptors may also be used for treating gastric or duodenal ulcer by virtue of their cytoprotective and anti-secretory properties. They may also be used as adjunctive therapy in combination with aspirin-like drugs and steroids to limit gastrointestinal side effects. EP3 agonists stimulate uterine smooth muscle and may be used to terminate pregnancy in human females. EP3 agonists are also useful in the cervical ripening process and could be used for inducing labor.
- Other potential therapeutic applications are in osteoporosis, constipation, renal disorders, sexual dysfunction, baldness, diabetes, cancer and in disorder of immune regulation.
- Many examples also have pronounced activity at the FP receptor, provisionally termed FPVASC associated with the vascular endothelium in the rabbit jugular vein preparation. Since such agents would be vasodilators they have potential in hypertension and any disease where tissue blood perfusion is compromised. Such indications include, but are not limited to, systemic hypertension, angina, stroke, retinal vascular diseases, claudication, Raynauds disease, diabetes, and pulmonary hypertension.
- The effects of the compounds of this invention on intraocular pressure are also provided in the following tables. The compounds were prepared at the said concentrations in a vehicle comprising 0.1
% polysorbate 80 and 10 mM TRIS base. Dogs were treated by administering 25 μl to the ocular surface, the contralateral eye received vehicle as a control. Intraocular pressure was measured by applanation pneumatonometry. Dog intraocular pressure was measured immediately before drug administration and at 6 hours thereafter. - Compounds 4g, 8t, 8u, 8v and 6g were examined and showed a pronounced ocular hypotensive effect in dogs.
EC30 (nM) Platelets Dog IOP Hyp/ AGN# FP EP1 EP3 FPVASC TP aggreg inhib (1 day) Miosis 4.2 >104 43 p.a. 1230 20 4010 NA NA 0.1%/−2.8 0.38/pinpt 82 >1044 >1041820 31 >104 0.1%/−4.2 0.79/pinpt 0.8 2000 400 178 9.2 2460 NA NA 0.1%/−6.0 0.6/pinpoint 3.5 >104 >1045000 3.6 >104 30 58 170 0.1%/−3.3 0.72*/pin 0.8 >104 pa 189 pa 1060 2.1 ˜104 NA NA 0.1%/−2.1 0.83/pinpt 10 >104 105 pa 2400 545 4740 NA NA 19 >104 83 2510 5400 0.1%/−3.6 0.01%/−2.5 0.38/pinpoint 0.83/mild 137 >5882 9 >104 44 1150 >7692 ˜104 0.1%/−4.3 0.01%/−1.7 0.67/pinpoint 0.54/mild 12 >104 355 3470 >833 3980 190 9000 pa >68966 0.1%/0 0.01%/−1.2 0.13/0 0.17/0 291 ˜104 2664 4 >104 1000 pa 6170 47 2450 0.1%/−3.3 1.13/pinpoint 7 >104 341 pa 8710 >7692 >104 3 >104 305 pa 2040 >7143 ˜104 0.1%/−4.5 0.01%/−2.9 1.38/pinpt 0.42/pinpt 0.8 >104 50 pa 2190 16 371 0.49 >104 >104 pa >104 7.7 2300 0.1%/−5.6 0.5/pinpt 4 >104 36 pa 7410 8.5 5080 0.1%/−4.8 1.0/pinpoint 503 1003 0.1%/−3.2 0.6/pinpoint 4230 28325 13 >104>104 = 104 pa 122 3530 33 21 >104 202 2940 53 0.70 NA 82 >104 0.1/−5.8 1.2/pinpoint -
Compound feFP/ rhFPv/ hFP hEP1 hTP # Structure OHL EP4 rtTPva htppl (Ca) (Ca) (Ca) 17a 43 112 ˜104 >104 17b 2950 >256,400 17c 115 6,510 18a 7.0 537 NA NA 18b 3.2 2.9 3498 >104 pa 19a 13 19b 23 19c 50 20a 7.9 6073 NA 20b 5.5 1036 20c 4.2 221 >>104 21a 5.6 1821 21b 6.8 189 21c 5.5 36 22a 169 22586 22b 424 22c 291 23a 5.0 387 >104 23b 3.4 108 117 23c 9.2 12 6.0 24 4.0 45 26 25 4.9 65 64 - The compounds of the invention may also be useful in the treatment of various pathophysiological diseases including acute myocardial infarction, vascular thrombosis, hypertension, pulmonary hypertension, ischemic heart disease, congestive heart failure, and angina pectoris, in which case the compounds may be administered by any means that effect vasodilation and thereby relieve the symptoms of the disease. For example, administration may be by oral, transdermal, parenterial, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes.
- The compounds of the invention may be used alone, or in combination with other of the known vasodilator drugs.
- The compounds of the invention may be formulated into an ointment containing about 0.10 to 10% of the active ingredient in a suitable base of, for example, white petrolatum, mineral oil and petroatum and lanolin alcohol. Other suitable bases will be readily apparent to those skilled in the art.
- The pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, by means of conventional dissolving or suspending the compounds, which are all either water soluble or suspendable. For administration in the treatment of the other mentioned pathophysiological disorders. The pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules make of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in liquid form that may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as in buffered salt solution. In addition, stabilizers may be added.
- In addition to being provided in a liquid form, for example in gelatin capsule or other suitable vehicle, the pharmaceutical preparations may contain suitable excipients to facilitate the processing of the active compounds into preparations that can be used pharmaceutically. Thus, pharmaceutical preparations for oral use can be obtained by adhering the solution of the active compounds to a solid support, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as inders such as starch, paste using for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, crosslinked polyvinyl pyrrolidone, agar, or algenic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which if desired, are resistant to gastric juices. For this purpose, concentrated sugar solutions may be used, which may optionally containing gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tables or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Suitable formulations for intravenous or parenteral administration include aqueous solutions of the active compounds. In addition, suspensions of the active compounds as oily injection suspensions may be administered. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, soribitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
- The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that further compounds with the desired pharmacological properties can be prepared in an analogous manner, and that the disclosed compounds can also be obtained from different starting compounds via different chemical reactions. Similarly, different pharmaceutical compositions may be prepared and used with substantially the same result. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims.
Claims (7)
1. A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula II:
wherein the hatched segments represent a bonds, the solid triangle represents a β bond, wavy line attachments indicate either the alpha (α) or beta (β) configuration; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, and —N(R5)SO2R6, wherein R5 represents hydrogen or CH2OR6 and R6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is ═O or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.
2. The method of claim 1 wherein the substituent on the heteroaryl radical is selected from the group consisting of lower alkyl, halogen, trifluoromethyl, COR1, COCF3, SO2NR1, SO2NH2, NO2 and CN.
3. A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution in said container comprising a compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle.
4. A method of treating glaucoma which comprises administering to a mammal having glaucoma a therapeutically effective amount of a compound represented by formula I:
wherein the wavy segments represent either an alpha (α) or beta (β) bond; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, and —N(R5)SO2R6, wherein R5 represents hydrogen or CH2OR6 and R6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is ═O or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.
6. A method of treating elevated intraocular pressure which comprises administering to a mammal having elevated intraocular pressure a therapeutically effective amount of a compound represented by formula I:
wherein the wavy segment represents either an alpha (α) or beta (β) bond; dashed bonds represent a double bond or a single bond, R is a substituted hetero aryl radical, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, and —N(R5)SO2R6, wherein R5 represents hydrogen or CH2OR6 and R6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical; Y is ═O or represents 2 hydrogen radicals and the pharmaceutically acceptable salts and esters thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/621,195 US20040044045A1 (en) | 1992-09-21 | 2003-07-15 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/948,056 US5352708A (en) | 1992-09-21 | 1992-09-21 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US15424493A | 1993-11-18 | 1993-11-18 | |
US08/371,339 US5607978A (en) | 1992-09-21 | 1995-01-11 | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US08/605,567 US5688819A (en) | 1992-09-21 | 1996-02-22 | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US08/726,921 US5834498A (en) | 1992-09-21 | 1996-10-07 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US09/185,403 US5972991A (en) | 1992-09-21 | 1998-11-03 | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US09/295,003 US6037364A (en) | 1992-09-21 | 1999-04-20 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US09/523,880 US6204287B1 (en) | 1992-09-21 | 2000-03-13 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US09/795,982 US6310087B2 (en) | 1992-09-21 | 2001-02-28 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US10/021,485 US6602900B2 (en) | 1992-09-21 | 2001-10-29 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US10/621,195 US20040044045A1 (en) | 1992-09-21 | 2003-07-15 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/021,485 Continuation US6602900B2 (en) | 1992-09-21 | 2001-10-29 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040044045A1 true US20040044045A1 (en) | 2004-03-04 |
Family
ID=27578580
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/021,485 Expired - Lifetime US6602900B2 (en) | 1992-09-21 | 2001-10-29 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US10/621,195 Abandoned US20040044045A1 (en) | 1992-09-21 | 2003-07-15 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/021,485 Expired - Lifetime US6602900B2 (en) | 1992-09-21 | 2001-10-29 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
Country Status (1)
Country | Link |
---|---|
US (2) | US6602900B2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011113855A3 (en) * | 2010-03-17 | 2011-11-17 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US9770508B2 (en) | 2012-09-12 | 2017-09-26 | Novaliq Gmbh | Semifluorinated alkane compositions |
US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
US11413323B2 (en) | 2018-10-12 | 2022-08-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7179820B2 (en) * | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
US7868035B2 (en) * | 2005-02-01 | 2011-01-11 | Allergan, Inc. | Therapeutic esters |
US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
RU2666603C2 (en) * | 2013-03-15 | 2018-09-11 | Аллерган, Инк. | Intraocular implants containing prostamides |
CN105188666A (en) | 2013-04-01 | 2015-12-23 | 阿勒根公司 | Microsphere drug delivery system for sustained intraocular release |
US9492316B2 (en) | 2013-10-31 | 2016-11-15 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
RU2730520C2 (en) * | 2013-12-13 | 2020-08-24 | Аллерган, Инк. | Solid forms of alpha, omega disubstituted dihydroxy cyclopentyl compound and methods for production and use thereof |
RU2017140078A (en) * | 2015-04-30 | 2019-05-30 | Аллерган, Инк. | COSMETIC METHOD AND ITS THERAPEUTIC APPLICATION TO REDUCE THE FATTY OF FAT TISSUE |
WO2019023211A1 (en) * | 2017-07-25 | 2019-01-31 | Allergan, Inc. | Solid complex comprising (z)-7-((1r,2r,3r,5s)-2-((s,e)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide, preparation and uses thereof |
US20220023095A1 (en) | 2020-07-21 | 2022-01-27 | Allergan, Inc. | Intraocular implant with high loading of a prostamide |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5422368A (en) * | 1988-09-06 | 1995-06-06 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES416865A1 (en) | 1972-07-13 | 1976-03-01 | Pfizer | 15-substituted-omega-pentanorprostaglandins |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
-
2001
- 2001-10-29 US US10/021,485 patent/US6602900B2/en not_active Expired - Lifetime
-
2003
- 2003-07-15 US US10/621,195 patent/US20040044045A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5422368A (en) * | 1988-09-06 | 1995-06-06 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5422369A (en) * | 1988-09-06 | 1995-06-06 | Kabi Pharmacia Ab | Prostaglanddin derivatives for the treatment of glaucoma or ocular hypertension |
US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US6037364A (en) * | 1992-09-21 | 2000-03-14 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US6204287B1 (en) * | 1992-09-21 | 2001-03-20 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US6310087B2 (en) * | 1992-09-21 | 2001-10-30 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10525062B2 (en) | 2010-03-17 | 2020-01-07 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US11324757B2 (en) | 2010-03-17 | 2022-05-10 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
WO2011113855A3 (en) * | 2010-03-17 | 2011-11-17 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US10555953B2 (en) | 2010-03-17 | 2020-02-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
US10058615B2 (en) | 2012-09-12 | 2018-08-28 | Novaliq Gmbh | Semifluorinated alkane compositions |
US10576154B2 (en) | 2012-09-12 | 2020-03-03 | Novaliq Gmbh | Semifluorinated alkane compositions |
US11583513B2 (en) | 2012-09-12 | 2023-02-21 | Novaliq Gmbh | Semifluorinated alkane compositions |
US9770508B2 (en) | 2012-09-12 | 2017-09-26 | Novaliq Gmbh | Semifluorinated alkane compositions |
US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
US11357738B2 (en) | 2015-09-30 | 2022-06-14 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
US11400132B2 (en) | 2016-09-23 | 2022-08-02 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
US11413323B2 (en) | 2018-10-12 | 2022-08-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Also Published As
Publication number | Publication date |
---|---|
US20020198249A1 (en) | 2002-12-26 |
US6602900B2 (en) | 2003-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6204287B1 (en) | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | |
US5834498A (en) | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | |
US6124344A (en) | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | |
US6602900B2 (en) | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | |
US6680337B2 (en) | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | |
EP0825980B1 (en) | Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension | |
US6376533B1 (en) | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | |
EP0585380B1 (en) | Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives | |
US6248783B1 (en) | Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents | |
US6380251B1 (en) | Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents | |
US20070219256A1 (en) | Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |